Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Targeted Next Generation Sequencing Improves Diagnosis in Unclassifiable Leukemic Indolent B-Cell Non-Hodgkin Lymphoma and Identifies a Subset with Recurrent MYD88 Mutations in a Prospective Multicentre Study

Matthew J Cross, MBBS, BSc, Grzegorz Pietka, PhD, Sarah Dunne, Leonora Conneely, Michael Hubank, PhD, Corinne De Lord, MD FRCPath, Michelle Furtado, MD FRCPath, PhD, Pawel Kaczmarek, MD PhD, Dima El-Sharkawi, Claire E. Dearden, MD FRCP, FRCPath, Kabir Mohammed, Alan Stewart Dunlop, MSc, BS, Ricardo Morilla, Karol Pal, PhD, Nikos Darzentas, PhD, David Gonzalez, PhD, Dorte Wren, PhDFRCPath, Sunil Iyengar, MD FRCPath, PhD

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-141542

Published: 2020

Journal Articles

The Value of Follow-up Following Complete Remission with Frontline Chemotherapy for DLBCL

Sarah Thompson, Tasneem Elnafie, Tatiana Elwes, Wilam Alfred, Alinane Munyenyembe, Kabir Mohammed, Bhupinder Sharma, MBBS, BSc(Hons) BM FRCR, Ian Chau, MD, David Cunningham, MD FRCP, FMedSci, Sunil Iyengar, MD FRCPath, PhD, Dima El-Sharkawi

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-141982

Published: 2020

Journal Articles

Risk Factors and Outcomes of Patients with Follicular Lymphoma Who Had Histologic Transformation at First Progression after First-Line Immunochemotherapy in the Gallium Study

Carla Casulo, Michael Herold, MD, Wolfgang Hiddemann, MD PhD, Sunil Iyengar, MD, Robert E. Marcus, FRCP, John F. Seymour, MBBS, PhD FRACP, Aino Launonen, MSc, Andrea Knapp, PhD, Tina G Nielsen, MD PhD, Farheen Mir, MBBS, MD

Blood (2019) 134 (Supplement_1): 5268.

https://doi.org/10.1182/blood-2019-123466

Published: 2019

Journal Articles

Procarbazine-Free Escalated Beacopdac in Frontline Therapy of Advanced Hodgkin Lymphoma Reduces Red Cell Transfusion Requirements and May Shorten Time to Menstrual Period Recovery Compared to Escalated Beacopp and Appears to be As Efficacious

Blood (2019) 134 (Supplement_1): 1564.

https://doi.org/10.1182/blood-2019-125256

Published: 2019

Journal Articles

Human Primary Mantle Cell Lymphoma Can Be Established in NOD/SCID/IL2Rγ-Null Mice

Sunil Iyengar, MD, Linda Ariza-McNaughton, MSc, Andrew James Clear, BSc, Amy Roe, Debra Lillington, PhD, David C Taussig, PhD, MRCP, FRCPath, John G Gribben, Simon Joel, Dominique Bonnet, PhD

Blood (2012) 120 (21): 1565.

https://doi.org/10.1182/blood.V120.21.1565.1565

Published: 2012

Journal Articles

Increased Tonic PI3K Signaling Through p110α Can Limit the Efficacy of P110δ-Selective Inhibition in Mantle Cell Lymphoma, Particularly with Multiple Relapse

Sunil Iyengar, MD, Andrew James Clear, BSc, Csaba Bödör, PhD, Lenushka Maharaj, Janet Matthews, Rebecca Auer, MD, Sameena Iqbal, John G Gribben, Simon Joel

Blood (2012) 120 (21): 1652.

https://doi.org/10.1182/blood.V120.21.1652.1652

Published: 2012

Journal Articles

PI3K Inhibition with GDC-0941 Has Greater Efficacy Compared to p110δ-Selective Inhibition with CAL-101 in Mantle Cell Lymphoma and May Be Particularly Advantageous in Multiply Relapsed Patients

Sunil Iyengar, MD, Andrew J. Clear, BSc, Andrew Owen, Lenushka Maharaj, MSc, Janet Matthews, Maria Calaminici, MD, Rebecca Auer, MD, Essam Ghazaly, MD, Sameena Iqbal, John G. Gribben, MD, DSc, Simon Joel, BSc(Hons), PhD

Blood (2011) 118 (21): 1654.

https://doi.org/10.1182/blood.V118.21.1654.1654

Published: 2011

NARROW

Targeted Next Generation Sequencing Improves Diagnosis in Unclassifiable Leukemic Indolent B-Cell Non-Hodgkin Lymphoma and Identifies a Subset with Recurrent MYD88 Mutations in a Prospective Multicentre Study

The Value of Follow-up Following Complete Remission with Frontline Chemotherapy for DLBCL

Risk Factors and Outcomes of Patients with Follicular Lymphoma Who Had Histologic Transformation at First Progression after First-Line Immunochemotherapy in the Gallium Study

Procarbazine-Free Escalated Beacopdac in Frontline Therapy of Advanced Hodgkin Lymphoma Reduces Red Cell Transfusion Requirements and May Shorten Time to Menstrual Period Recovery Compared to Escalated Beacopp and Appears to be As Efficacious

Human Primary Mantle Cell Lymphoma Can Be Established in NOD/SCID/IL2Rγ-Null Mice

Increased Tonic PI3K Signaling Through p110α Can Limit the Efficacy of P110δ-Selective Inhibition in Mantle Cell Lymphoma, Particularly with Multiple Relapse

PI3K Inhibition with GDC-0941 Has Greater Efficacy Compared to p110δ-Selective Inhibition with CAL-101 in Mantle Cell Lymphoma and May Be Particularly Advantageous in Multiply Relapsed Patients

Email alerts

ASH Publications

American Society of Hematology

Targeted Next Generation Sequencing Improves Diagnosis in Unclassifiable Leukemic Indolent B-Cell Non-Hodgkin Lymphoma and Identifies a Subset with Recurrent MYD88 Mutations in a Prospective Multicentre Study

The Value of Follow-up Following Complete Remission with Frontline Chemotherapy for DLBCL

Risk Factors and Outcomes of Patients with Follicular Lymphoma Who Had Histologic Transformation at First Progression after First-Line Immunochemotherapy in the Gallium Study

Procarbazine-Free Escalated Beacopdac in Frontline Therapy of Advanced Hodgkin Lymphoma Reduces Red Cell Transfusion Requirements and May Shorten Time to Menstrual Period Recovery Compared to Escalated Beacopp and Appears to be As Efficacious

Human Primary Mantle Cell Lymphoma Can Be Established in NOD/SCID/IL2Rγ-Null Mice

Increased Tonic PI3K Signaling Through p110α Can Limit the Efficacy of P110δ-Selective Inhibition in Mantle Cell Lymphoma, Particularly with Multiple Relapse

PI3K Inhibition with GDC-0941 Has Greater Efficacy Compared to p110δ-Selective Inhibition with CAL-101 in Mantle Cell Lymphoma and May Be Particularly Advantageous in Multiply Relapsed Patients

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only